Natera Inc (NTRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Natera Inc (NTRA) has a cash flow conversion efficiency ratio of 0.043x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($73.89 Million) by net assets ($1.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Natera Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Natera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Natera Inc for a breakdown of total debt and financial obligations.
Natera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natera Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northern Trust Corporation
NASDAQ:NTRS
|
0.041x |
|
WUS Printed Circuit Kunshan Co Ltd
SHE:002463
|
0.059x |
|
TRIP.COM GROUP DL-00125
F:CLVB
|
N/A |
|
Tapestry Inc
NYSE:TPR
|
1.961x |
|
Kongsberg Gruppen ASA
OL:KOG
|
0.565x |
|
adidas AG
F:ADS
|
0.105x |
|
Devon Energy Corporation
NYSE:DVN
|
0.101x |
|
Fortis Inc
TO:FTS
|
0.039x |
Annual Cash Flow Conversion Efficiency for Natera Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Natera Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see NTRA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.71 Billion | $215.30 Million | 0.126x | +10.79% |
| 2024-12-31 | $1.20 Billion | $135.66 Million | 0.113x | +135.17% |
| 2023-12-31 | $765.33 Million | $-246.96 Million | -0.323x | +47.22% |
| 2022-12-31 | $705.74 Million | $-431.50 Million | -0.611x | -19.15% |
| 2021-12-31 | $653.30 Million | $-335.24 Million | -0.513x | -36.71% |
| 2020-12-31 | $486.24 Million | $-182.51 Million | -0.375x | -64.90% |
| 2019-12-31 | $278.71 Million | $-63.44 Million | -0.228x | +89.63% |
| 2018-12-31 | $32.16 Million | $-70.58 Million | -2.195x | +42.98% |
| 2017-12-31 | $25.42 Million | $-97.83 Million | -3.849x | -453.40% |
| 2016-12-31 | $106.48 Million | $-74.05 Million | -0.695x | -239.66% |
| 2015-12-31 | $184.76 Million | $-37.83 Million | -0.205x | -234.43% |
| 2014-12-31 | $-171.34 Million | $10.49 Million | -0.061x | -143.51% |
| 2013-12-31 | $-171.51 Million | $-24.13 Million | 0.141x | +18.75% |
| 2012-12-31 | $-125.80 Million | $-14.90 Million | 0.118x | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more